The Science of HER2-low Breast Cancer and Implications for the Pathology Team

This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies. Claim CME/CMLE credit at store.ascp.org... Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC. Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.